Sign in
Taking people in United StatesPhase 2

Tests ORC-13661 to prevent hearing loss from amikacin treatment

Tests a study drug against placebo to prevent hearing loss in adults with NTM infection.

Key facts

Who runs it
Kevin Winthrop
Where
Baltimore, Charleston, Denver, Manhasset, Portland, Rochester, San Francisco, and Tyler, United StatesSee the 8 sites
Trial code
Registry title
Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin
Status
Recruiting
Phase
Phase 2
People taking part
105 people, planned
Started
2 Jun 2025
Expected to end
29 Feb 2028
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • ORC-13661
  • Placebo
Record updated
1 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a non-tuberculous mycobacterium (NTM) lung infection who will have IV amikacin treatment. It tests whether the study drug ORC-13661 can prevent hearing loss caused by amikacin.

Age
Older than 18 and younger than 80 years.
Sex
All sexes can join.
Disease stage
NTM infection that meets the ATS/IDSA guidelines for IV aminoglycoside treatment. IV amikacin treatment is expected to last at least 30 days.
Earlier treatment
No systemic aminoglycoside antibiotic and no amikacin in the 6 months before the first amikacin dose or randomization.
Biomarker or test result
Amikacin resistance must not be known (MIC >64 excludes).

Main reasons for not taking part

  • Known amikacin resistance (MIC >64)
  • ECG with QTcF interval of 450 msec or more, or heart rhythm problems
  • Taking strong CYP3A4 inducers or inhibitors, such as rifampin, rifabutin or clarithromycin
  • Eardrum damage, earlier sudden or congenital hearing loss, Meniere's disease, or profound hearing loss in both ears
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

  • Providing informed consent, documented by signing and dating the currently valid informed consent form
  • Considered by the Investigator to have unimpaired consent capacity, without reliance on a legally authorized representative
  • Stated willingness and ability to comply with study procedures and availability for the duration of the study
  • Aged > 18 and < 80
  • NTM infection meeting current Pulmonary NTM guidelines from the American Thoracic Society and the Infectious Diseases Society of America (ATS/IDSA) for systemic (IV) aminoglycoside therapy
  • Anticipated duration of IV amikacin treatment of at least 30 days at time of study entry
  • Statement of ability to take oral medication and adhere to the daily dosing regimen
  • For females of reproductive potential: If they are of childbearing potential, they must agree in writing to practice an effective double barrier method of contraception from the signing of the informed consent form until 1 month following discontinuation of study drug treatment or agree to practice true abstinence, when this is consistent with the preferred and usual lifestyle of the subject
  • For males of reproductive potential: Agree to practice effective barrier contraception from the signing of the informed consent form until 3 months (one spermatogenesis cycle) following the last dose of study drug or agree to practice true abstinence

Who cannot take part

  • Received a systemic aminoglycoside antibiotic within 6 months prior to planned first dose of amikacin
  • ECG at Screening or prior to randomization with abnormalities that, in the Investigator's judgment, might predispose patient to clinically significant arrhythmia
  • Patients taking strong CYP3A4 inducers such as rifampin and rifabutin in the 7 days prior to randomization or have the need for ongoing treatment with concomitant oral or intravenous therapy with strong CYP3A4 inducers during the study. If an additional antibiotic is needed, then azithromycin will be used
  • Patients taking strong CYP3A4 inhibitors such as clarithromycin in the 7 days prior to randomization or the need for ongoing treatment with concomitant oral or intravenous therapy with strong CYP3A4 inhibitors during the study. If an additional antibiotic is needed, then azithromycin will be used
  • Patients taking clofazimine or bedaquiline AND who also have congestive heart failure, significant ventricular arrhythmia, uncorrected hypokalemia, or ECG (single at Screening, mean of triplicate prior to randomization) showing QRS > 120 msec or heart rate < 50 bpm
  • Patients with amikacin exposure within the 6 months prior to randomization
  • Current or anticipated use of excluded concomitant medications as specified in Section 6.5
  • Progressive liver disease (Child-Pugh B or C) which would affect or invalidate interpretation of change from the baseline liver function tests over the course of the study
  • Signs of disturbed integrity of the tympanic membrane, determined by otoscopy or tympanometry, including chronic perforation or middle ear or ear canal inflammation or effusion
  • History of congenital hearing loss, otological surgery (excluding myringotomy tubes or simple tympanoplasty healed and currently intact), sudden hearing loss, or Meniere's disease
  • History of active malignancy, either untreated or under active treatment
  • Female relying on menopausal status for contraception who does not have Follicle-Stimulating Hormone (FSH) level consistent with that condition and who does not agree in writing to using a double barrier method of contraception
  • ECG at Screening or prior to randomization (mean of triplicate values) with QT interval corrected using Fridericia's formula (QTcF interval) ≥ 450 msec
  • History of risk factors for Torsades des Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
  • Presence of any circumstance, condition, ECG or laboratory finding that, based on investigator judgment, would interfere with study procedures or assessments or present to the patient an unreasonable risk from participation in this study
  • Female of childbearing potential who does not have a negative serum pregnancy test and does not agree in writing to using a double barrier method of contraception
  • Patients with known amikacin resistance (MIC >64)
  • Bilateral profound hearing loss (>90 Decibels [dB] HL) at all test frequencies
  • Conductive hearing loss evidenced by average air-bone-gaps >15 dB HL for 0.25-4.0 kilohertz (kHz)
  • Venous access not adequate for performance of study procedures
  • Pregnant or lactating
  • Currently under correctional supervision (imprisoned, on probation or parole)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in United States

  • Johns Hopkins UniversityBaltimore, United StatesContact: Pooja AkoijamTaking people
  • Medical University of South CarolinaCharleston, United StatesContact: Cameron MathisonTaking people
  • National Jewish HealthDenver, United StatesContact: Shane Hopkins, RNTaking people
  • Northwell HealthManhasset, United StatesContact: Andrew DiazTaking people
  • Oregon Health Science UniversityPortland, United StatesContact: Violet TiffeeTaking people
  • Mayo ClinicRochester, United StatesContact: Daniel BouchatNo longer taking part
  • University of California San FranciscoSan Francisco, United StatesContact: Amira Flores BanuelosTaking people
  • University of Texas Health Science CenterTyler, United StatesContact: Kimberly GreenleeTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to test the effectiveness of the study drug, ORC-13361, in preventing hearing loss in patients with NTM infection who are undergoing treatment with IV amikacin therapy. The main question this study aims to answer is:

Read full original descriptionShow less

* Is ORC-13661 effective for preventing or lessening hearing loss induced by amikacin treatment? * Is ORC-13661 effective for preventing or lessening other measures of hearing impairment?

Participants will be asked to take a study drug while they are being treated with IV amikacin. Participants will take study drug for 90 days or until the end of their amikacin treatment, whichever comes first. During this time, researchers will gather clinical data on the participants' health.

Researchers will compare three groups - two groups taking different doses of the study drug and one group taking a placebo drug - to see if dose of drug has any effect on preventing hearing loss. A placebo is a look-alike substance that contains no active drug.

The 3 groups in the trial

  • High Dose ORC-13661Treatment being tested

    This arm is a daily treatment regimen of study drug (ORC-13661) with a loading dose of 150mg followed by a daily dose of 30mg. Treatment regimen will run concurrently with treatment with IV amikacin. Study drug treatment will continue until treatment with IV amikacin ends or 90 days, whichever is earlier.

    Treatment: ORC-13661

  • Low Dose ORC-13661Treatment being tested

    This arm is a daily treatment regimen of study drug (ORC-13661) with a loading dose of 60mg capsules followed by a daily dose of 12mg capsules. Treatment regimen will run concurrently with treatment with IV amikacin. Study drug treatment will continue until treatment with IV amikacin ends or 90 days, whichever is earlier.

    Treatment: ORC-13661

  • PlaceboPlacebo, for comparison

    This arm is a daily treatment regimen of a placebo with a loading dose and a daily dose of placebo capsules to match the treatment arms. Placebo regimen will run concurrently with treatment with IV amikacin. Placebo regimen will continue until treatment with IV amikacin ends or 90 days, whichever is earlier.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Phase 2 Study of the Efficacy and Safety of ORC-13661 for the Prevention of Drug-Induced Hearing Loss in Patients Receiving Intravenous Amikacin Therapy for Non-Tuberculous Mycobacterium Disease
Plain-language title
Tests ORC-13661 to prevent hearing loss from amikacin treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05730283, who can take part
Record updated
1 October 2026